The Nevada Assembly has amended and advanced a Senate-passed joint resolution calling on Congress to reschedule certain psychedelics, streamline research and provide protections for people using the substances in compliance with state law.
On the chamber floor on Thursday, lawmakers voted 36-6 to advance the measure—SJR 10, from Sen. Rochelle Nguyen (D)—which now returns to the Senate to consider changes made in the Assembly.
The resolution cites research demonstrating the therapeutic potential of psychedelics in the treatment of serious mental health conditions and calls on the federal government to “reschedule psilocybin, psilocin, DMT, ibogaine, mescaline and MDMA to a schedule that better reflects the therapeutic value, low potential for abuse and safety for use under medical supervision of those compounds.”
It also points out that there have been federal developments on the issue, including the Food and Drug Administration (FDA) designation of certain psychedelics as “breakthrough therapies” and research that’s being funded to explore the substances at the Department of Defense (DOD) and U.S. Department of Veterans Affairs (VA).
The measure urges Congress to increase funding for further research, establish a “streamlined process for approving and conducting research with psychedelic compounds,” and reschedule psilocybin, psilocin, DMT, ibogaine, mescaline and MDMA under the Controlled Substances Act (CSA).
Further, it calls for the establishment of “legal protection against federal prosecution for individuals and entities complying with state law concerning the supervised adult use of psychedelic compounds and require states to enter research partnerships with the Attorney General under the Controlled Substances Act to study the public health outcomes of such state programs.”
Hellbound and Down 